Bendamustine
- Generic Name
- Bendamustine
- Brand Names
- Belrapzo, Bendeka, Treanda, Vivimusta
- Drug Type
- Small Molecule
- Chemical Formula
- C16H21Cl2N3O2
- CAS Number
- 16506-27-7
- Unique Ingredient Identifier
- 9266D9P3PQ
- Background
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophili...
- Indication
Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
- Associated Conditions
- Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma
- Associated Therapies
- -
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02954406
- Locations
- 🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Tucson, Arizona, United States
Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 29
- Registration Number
- NCT02951156
- Locations
- 🇦🇺
Monash Health, Clayton, Victoria, Australia
🇮🇹Istituto Clinico Humanitas, Rozzano, MI, Italy
🇺🇸City of Hope, Duarte, California, United States
Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 926
- Registration Number
- NCT02950051
- Locations
- 🇮🇱
Kaplan Medical Center, Rechovot, Israel
🇳🇱Canisius-Wilhelmina ZH, Nijmegen, Netherlands
🇳🇱Antonius Ziekenhuis Sneek, Sneek, Netherlands
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
- First Posted Date
- 2016-07-19
- Last Posted Date
- 2016-07-19
- Lead Sponsor
- Pusan National University Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT02836639
- Locations
- 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia
- First Posted Date
- 2016-06-14
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- St. Petersburg State Pavlov Medical University
- Target Recruit Count
- 27
- Registration Number
- NCT02799147
- Locations
- 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation
CyBeR Association in Relapsed/Refractory DLBCL
- Conditions
- Interventions
- First Posted Date
- 2016-05-03
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 78
- Registration Number
- NCT02758925
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2016-04-11
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Celgene
- Target Recruit Count
- 106
- Registration Number
- NCT02733042
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Jefferson Medical Oncology Associates, Philadelphia, Pennsylvania, United States
🇫🇷Centre Hospitalier Universitaire d'Avicennes, Bobigny Cedex, France
Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 18
- Registration Number
- NCT02728531
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
- Conditions
- Interventions
- First Posted Date
- 2016-02-23
- Last Posted Date
- 2020-06-11
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 66
- Registration Number
- NCT02689141
- Locations
- 🇩🇪
German CLL Study Group, Cologne, Germany
Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
- First Posted Date
- 2015-12-10
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 551
- Registration Number
- NCT02626455
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center- Bergen, New York, New York, United States
🇧🇷Hospital de Clinicas de Porto Alegre | Clinical Research Center - Surgery Research Center, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Irmandade da Santa Casa de Misericordia de Porto Alegre | Hospital Sao Francisco - Centro Medico Pesquisa Clinica Cardiologia, Porto Alegre, Rio Grande Do Sul, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.